Study Evaluating the Efficacy and Safety of Etanercept

Phase 4 Completed 40 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the efficacy of etanercept 25 mg administered subcutaneously twice-weekly for 12 weeks in patients with active RA for whom classical antirheumatic therapy is insufficient or inappropriate.

Timeline

Start: 2003-01
Primary completion: —
Completion: 2005-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	25 mg	Subcutaneous

Study Evaluating the Efficacy and Safety of Etanercept

Summary

Timeline

Drugs

Indications